AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway.
AKT/β-catenin pathway
SC66
apoptosis
epithelial-to-mesenchymal transition
glioblastoma multiforme
proliferation
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
03
2020
accepted:
06
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most common intracranial malignancy in adults with the highest degree of malignancy and mortality. Due to its nature of diffuse invasiveness and high migration, GBM lacks an effective treatment strategy and is associated with poor prognosis. SC66 is a novel AKT inhibitor that has been reported to exert antiproliferative activity in many types of cancer cells. However, it remains unclear whether SC66 has antitumor effects in GBM. In this study, we found SC66 obviously suppressed U87 and U251 cell proliferation and EMT- mediated cell migration and invasion. Moreover, SC66 induced GBM cells apoptosis and arrested cell cycle in G0/G1 phase. Furthermore, SC66 also downregulated AKT signaling pathway in a concentration dependent manner. We also found the level of β-catenin nuclear translocation was prominently downregulated after SC66 treatment. Meanwhile, TCF/LEF luciferase report assay indicated that the activity of TCF/LEF was remarkably suppressed. Elevating β-catenin activity by using IM12 rescued SC66 inhibition-mediated GBM cell proliferation and metastasis. In addition, SC66 showed significantly suppressed the tumorigenicity compared to the control group in the xenograft mouse model. In conclusion, our study demonstrated that SC66 exerts prominently antitumor efficiency in GBM cells
Identifiants
pubmed: 32848734
doi: 10.3389/fphar.2020.01102
pmc: PMC7411127
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1102Informations de copyright
Copyright © 2020 Gao, Liu, Xu, Deng, Liu, Yuan, Tan, Sun, Xu, Zhang, Qi, Han, Yang, Geng, Jiang and Chen.
Références
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91
pubmed: 21464312
Cancer Cell Int. 2018 Jun 28;18:90
pubmed: 29988358
Int J Mol Sci. 2019 Jul 09;20(13):
pubmed: 31323961
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Cancer Lett. 2015 Apr 1;359(1):107-16
pubmed: 25592037
Bioorg Med Chem. 2010 Sep 15;18(18):6785-95
pubmed: 20708937
Oncotarget. 2015 Jan 30;6(3):1707-22
pubmed: 25596737
PLoS One. 2016 May 5;11(5):e0155168
pubmed: 28886011
Br J Clin Pharmacol. 2016 Oct;82(4):943-56
pubmed: 27232857
Cell Death Dis. 2019 Apr 11;10(4):322
pubmed: 30975980
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
Brain Res. 2019 Aug 15;1717:117-126
pubmed: 30935831
J Exp Clin Cancer Res. 2018 Jul 3;37(1):132
pubmed: 29970196
J Clin Oncol. 2009 Sep 1;27(25):4155-61
pubmed: 19636006
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452
pubmed: 28031556
Semin Cancer Biol. 2009 Feb;19(1):25-31
pubmed: 19130886
Autophagy. 2017 May 4;13(5):900-913
pubmed: 28521610
J Exp Clin Cancer Res. 2017 Nov 6;36(1):155
pubmed: 29110682
Cancers (Basel). 2019 Mar 06;11(3):
pubmed: 30845654
Cell Death Dis. 2018 Jan 26;9(2):136
pubmed: 29374154
Cancer Cell Int. 2019 May 9;19:124
pubmed: 31168297
Cell. 2007 Jun 29;129(7):1261-74
pubmed: 17604717
Curr Opin Cell Biol. 2017 Apr;45:62-71
pubmed: 28343126
Biomed Res Int. 2017;2017:7403747
pubmed: 29259986
Cell Physiol Biochem. 2018;51(6):2536-2546
pubmed: 30562758
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946